Long-term secondary prophylaxis in children, adolescents and young adults with von willebrand disease: Results of a cohort study

Thrombosis and Haemostasis

Volumn 105, Issue 4, 2011, Pages 597-604

  Halimeh, Susan ^a   Krümpel, Anne ^b   Rott, Hannelore ^a   Bogdanova, Nadja ^b   Budde, Ulrich ^c   Manner, Daniela ^b   Faeser, Britta ^a   Mesters, Rolf ^b   Nowak Göttl, Ulrike ^b,d  

^a Medical Thrombosis and Hemophilia treatment Center Duisburg   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c MRI Institute Hamburg Altona   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Children; Inhibitor development; Long term prophylaxis; Von willebrand disease; Young adults

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; HEMOGLOBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; WILATE; WILLFACT;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMARTHROSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFANT; MALE; MEDICAL DECISION MAKING; NORMAL VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SECONDARY PREVENTION; TREATMENT DURATION; VON WILLEBRAND DISEASE;

ADOLESCENT; CHILD; CLINICAL PROTOCOLS; COHORT STUDIES; FACTOR VIII; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HEMORRHAGE; HUMANS; MALE; TREATMENT OUTCOME; VON WILLEBRAND DISEASES; YOUNG ADULT;

EID: 79955414994     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-09-0616     Document Type: Article

References (27)

1. Bolton-Maggs PHB, Lillicrap D, Goudemand J, et val. Von Willebrand disease update: diagnostic and treatment dilemmas. Hemophilia 2008; 14 (Suppl 3): 56-61.
2. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101: 2089-2093.
3. Ruggeri ZM, Pareti FI, Mannucci PM, et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980; 302: 1047-1051.
4. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 1236-1239.
5. Federici AB. Prophylaxis of bleeding episodes in patients with von Willebrand's disease. Blood Transfus 2008; 6 (Suppl 2): s26-s32.
6. Makris M. Gastrointestinal bleeding in von Willebrand disease. Thromb Res 2006; 118 (Suppl 1): S13-S7.
7. Federici AB, Castaman F, Franchini M, et al. Clinical use of Haemate P in inherited von Willebrand disease: a cohort study on 100 Italian patients. Haematologica 2007; 92: 944-951.
8. Kadir RA, Chi C. Women and von Willebrand disease. Controversies in diagnosis and management. Sem Thromb Haemost 2006; 32: 605-615.
9. Berntorp E. Prophylaxis and treatment of bleeding complications in von Willebrand type 3. Sem Thromb Haemost 2006; 32: 621-625.
10. Lethagen S. Clinical experience of prophylactic treatment in von Willebrand disease. Thromb Res 2006; 118 (Suppl 1): S9-S11.
11. Berntorp E. Prophylaxis in von Willebrand disease. Haemophilia 2008; 14 (Suppl 5): 47-53.
12. Abshire T. The role of prophylaxis in the management of von Willebrand disease: today and tomorrow. Thromb Res 2009; 124 (Suppl 1): 15-19.
13. Mannucci PM, Franchini M, Castaman G, et al., on behalf of AICE. Evidencebased recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7: 117-126.
14. Lillicrap D, Poon MC, Walker I, et al. Efficacy and safety of the factor VIII/von Willebrand factor concentrate Haemate P/Humate P: Ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87: 224-230.
15. Franchini M, Rosetti G, Tagliaferri A, et al. Efficacy and safety of factor VIII/von Willebrand factor concentrate (Haemate P) preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica 2003; 88: 1279-1282.
16. Thompson AR, Gill JC, Ewenstein BM, et al. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/von Willebrand factor concentrate Humate P. Haemophilia 2004; 10: 42-51.
17. Lethagen S, Kyrle PA, Castaman G, et al. Von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007; 5: 1420-1430.
18. Abshire TC. Prophylaxis and von Willebrand disease. Thromb Res 2006; 118 (Suppl 1): S3-S7.
19. Rodeghiero F, Castaman G, Torsetto A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international multicenter study. J Thromb Haemost 2005; 3: 2619-2626.
20. Michiels JJ, Berneman Z, Gadisseur A, et al. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease. Clin Applied Thromb Haemost 2006; 12: 397-420.
21. Nichols WL, Hultin MB, James AH, et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
22. Keeney S, Bowen D, Cumming A, et al., on behalf of the UK hemophilia centre doctors' organization (UKHCDO). The molecular analysis of von Willebrand disease: A guideline from the UK haemophilia centre doctors' organization haemophilia genetics laboratory network. Haemophilia 2008; 14: 1099-1111.
23. Nuss R, Kilcoyne RF, Geraghty S, et al. MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. Haemophilia 2000; 6: 162-169.
24. James AH, Kouides PA, Kadir R, et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol 2009; 201: 12e 1-8.
25. Federici AB, Gianniello F, Mannucci PM. Secondary long-term prophylaxis in von Willebrand disease: an Italian cohort study. Haematologica reports 2005; 1: 15-20
26. Gouw SC, van der Bom JG, Auerswald G, et al., for the CANAL study group. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-4697.
27. Berntorp E, Abshire T, vWD PN Steering Committee. The von Willebrand disease prophylaxis network (vWD PN). Thromb Res 2006; 118 (Suppl 1): S19-S22.